ArticleACS omega2025
Multitechnique Approach for Xylazine Detection: Chemical Spot Tests, Immunoassays, and Scanning Electron Microscopy.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The infiltration of xylazine into the illicit drug supply, particularly as a fentanyl adulterant, has raised significant safety concerns due to its severe toxicological effects and the absence of an effective antidote for targeted therapeutic intervention. Despite the growing implications of xylazine in overdose cases, presumptive testing methods for its detection remain underdeveloped in forensic and public health settings. This study addresses the urgent need for reliable screening tools by evaluating the applicability of chemical spot tests, microcrystalline tests, commercially available xylazine immunoassay test strips, and other field-deployable drug test kits. A comprehensive panel of chemical spot test reagents was tested, and cobalt thiocyanate, Eosin Y (pH 7.0), and Liebermann, Mandelin, Mecke, Marquis, Scott, and Young reagents produced distinct and rapid color changes with xylazine. In parallel, different microcrystalline test reagents were evaluated, and the resulting microcrystal morphology was assessed by using light microscopy and scanning electron microscopy (SEM). Gold chloride reagent yielded immediate, reproducible, and well-defined microcrystals across different xylazine formulations, establishing it as the most effective reagent for microcrystalline testing. All xylazine test strips yielded clear positive test results when tested with xylazine. In contrast, many commercial and on-site screening tools displayed cross-reactivity or false-positive results with xylazine, raising concerns about its specificity and reliability. These findings highlight the need to develop and validate xylazine-specific presumptive screening tests to facilitate forensic investigations, support harm reduction efforts, and enable informed, safer decision-making by people who use drugs (PWUDs).
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.